Radiotherapy in pediatric pilocytic astrocytomas: A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH)
Mueller K, Gnekow A, Falkenstein F, Scheiderbauer J, Zwiener I, Pietsch T, Warmuth-Metz M, Voges J, Nikkhah G, Flentje M, Combs SE, Vordermark D, Kocher MS, Kortmann RD (2013)
Publication Type: Journal article
Publication year: 2013
Journal
Book Volume: 189
Pages Range: 647-655
Journal Issue: 8
DOI: 10.1007/s00066-013-0357-7
Abstract
Purpose: We evaluated clinical outcomes in the subset of patients who underwent radiotherapy (RT) due to progressive pilocytic astrocytoma within the Multicenter Treatment Study for Children and Adolescents with a Low Grade Glioma HIT-LGG 1996. Patients and methods: Eligibility criteria were fulfilled by 117 patients. Most tumors (65 %) were located in the supratentorial midline, followed by the posterior fossa (26.5 %) and the cerebral hemispheres (8.5 %). Median age at the start of RT was 9.2 years (range 0.7-17.4 years). In 75 cases, external fractionated radiotherapy (EFRT) was administered either as first-line nonsurgical treatment (n = 58) or after progression following primary chemotherapy (n = 17). The median normalized total dose was 54 Gy. Stereotactic brachytherapy (SBT) was used in 42 selected cases. Results: During a median follow-up period of 8.4 years, 4 patients (3.4 %) died and 33 (27.4 %) experienced disease progression. The 10-year overall (OS) and progression-free survival (PFS) rates were 97 and 70 %, respectively. No impact of the RT technique applied (EFRT versus SBT) on progression was observed. The 5-year PFS was 76 ± 5 % after EFRT and 65 ± 8 % after SBT. Disease progression after EFRT was not influenced by gender, neurofibromatosis type 1 (NF1) status, tumor location (hemispheres versus supratentorial midline versus posterior fossa), age or prior chemotherapy. Normalized total EFRT doses of more than 50.4 Gy did not improve PFS rates. Conclusion: EFRT plays an integral role in the treatment of pediatric pilocytic astrocytoma and is characterized by excellent tumor control. A reduction of the normalized total dose from 54 to 50.4 Gy appears to be feasible without jeopardizing tumor control. SBT is an effective treatment alternative. © 2013 Springer Heidelberg Berlin.
Involved external institutions
Universität Leipzig
Germany (DE)
Universitätsklinikum Augsburg
Germany (DE)
Johannes Gutenberg-Universität Mainz (JGU)
Germany (DE)
Universitätsklinikum Bonn
Germany (DE)
Julius-Maximilians-Universität Würzburg
Germany (DE)
Otto-von-Guericke-Universität Magdeburg
Germany (DE)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Martin-Luther-Universität Halle-Wittenberg (MLU)
Germany (DE)
Universität zu Köln
Germany (DE)
Germany (DE)
Universitätsklinikum Augsburg
Germany (DE)
Johannes Gutenberg-Universität Mainz (JGU)
Germany (DE)
Universitätsklinikum Bonn
Germany (DE)
Julius-Maximilians-Universität Würzburg
Germany (DE)
Otto-von-Guericke-Universität Magdeburg
Germany (DE)
Albert-Ludwigs-Universität Freiburg
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Martin-Luther-Universität Halle-Wittenberg (MLU)
Germany (DE)
Universität zu Köln
Germany (DE)
How to cite
APA:
Mueller, K., Gnekow, A., Falkenstein, F., Scheiderbauer, J., Zwiener, I., Pietsch, T.,... Kortmann, R.-D. (2013). Radiotherapy in pediatric pilocytic astrocytomas: A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). Strahlentherapie und Onkologie, 189(8), 647-655. https://dx.doi.org/10.1007/s00066-013-0357-7
MLA:
Mueller, K., et al. "Radiotherapy in pediatric pilocytic astrocytomas: A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH)." Strahlentherapie und Onkologie 189.8 (2013): 647-655.
BibTeX: Download